










 





Immune Design Appoints Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer (NASDAQ:IMDZ)

























 



Facebook
Google
LinkedIn
Twitter
Email
RSS





Oct 4, 2016



 Previous Release | Next Release 


PDF

Add to Briefcase
File is in Briefcase



Immune Design Appoints Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer

SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct.  04, 2016  (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer. "Sergey's extensive experience and successful track record in immunology and in the various stages of clinical oncology drug development, including registration trials and regulatory submissions and reviews, make him the optimal leader of our medical team," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer at Immune Design. "His esteemed career as an immunologist and oncologist spans industry, academia and clinical practice and will bring invaluable expertise and insight to guide the further advancement of our current Phase 2 stage products and our next-generation approaches in the field of cancer immunotherapy."     A board-certified, U.S. licensed hematologist/oncologist with more than 20 years of experience in immunology and oncology, Dr. Yurasov joins Immune Design from Clovis Oncology, where he most recently served as Senior Vice President, Clinical Development overseeing all clinical activities for its rociletinib, rucaparib and lucitanib programs, including regulatory approval and launch support for rociletinib and rucaparib.  Prior to Clovis, Dr. Yurasov served as Associate Vice-President, Global Medicine Science, at ImClone Systems, a subsidiary of Eli Lilly & Co. where he led the development of ramucirumab culminating in the FDA submission for second line non-small cell lung cancer indication. He also served at Hoffman-La Roche as Clinical Director of Oncology, Pharma Research and Early Development. Prior to his industry experience, Dr. Yurasov was Assistant Professor of Clinical Investigation at Rockefeller University, where he was the principal investigator for NIH funded translational immunology research, and Clinical Instructor in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center, where he was an attending physician. Dr. Yurasov received his M.D. from the Russian State Medical University and his Ph.D. in medical sciences from the Research Institute for Pediatric Oncology in Moscow, Russia.  He thereafter completed his residency in general pediatrics at Albert Einstein College of Medicine/Jacobi Medical Center and his subspecialty training in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center while serving as a research fellow at The Rockefeller University in Dr. M. Nussenzweig's laboratory. "Immune Design's immunotherapy approaches offer a promising approach to address the shortcomings of existing therapies, either alone or in combination with other agents," said Dr. Yurasov. "It is rewarding to be involved in such innovative science at the forefront of cancer research. I am pleased to join this distinguished team and look forward to help guide the development of these innovative product candidates." About Immune Design Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases.  CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVex® and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.Media Contact
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com 
206-769-9219

Investor Contact
Shari Annes
Annes Associates
sannes@annesassociates.com
650-888-0902







 








Immune Design Appoints Sergey Yurasov, M.D., Ph.D. As Senior Vice President Of Clinical Development And Chief Medical Officer - TheStreet




































































 

 




















Action Alerts PLUS

Access AAPJim Cramer's Best Stocks for 2017Charitable Trust PortfolioMost Recent Trade Alert25 Investing Rules10 Trading Commandments

Real Money

Access RM25 Rules of InvestingJim Cramer's Best Stocks for 201710 CommandmentsStressed Out StocksCramer's Blog

Cramer
Mad Money
ETFs
Futures
Markets
Much More

BanksBiotechRetailTechPersonal FinanceRetirementFinancial Advisor CenterHow to SpendOptionsFixed IncomeVideo










Privacy Policy|Terms of Use© 1996- TheStreet Inc. All rights reserved
















                                DJIA
                            







                                NASDAQ
                            







                                S&P 500
                            






Market Data updated






Sign In




Your Membership(s)








Your Account





Account Preferences


Alerts


Newsletters







Subscribe





Logout



Subscribe

Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Income Seeker
Quant Ratings
Real Money
Real Money Pro
Stocks Under $10
Top Stocks
Trifecta Stocks
Real Money Pro Portfolio
Chairman's Club
Compare All 
Chatter on the Street













































 








































Immune Design Appoints Sergey Yurasov, M.D., Ph.D. As Senior Vice President Of Clinical Development And Chief Medical Officer






GlobeNewswire



Oct 4, 2016 8:00 AM EDT













 




























































 SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer. "Sergey's extensive experience and successful track record in immunology and in the various stages of clinical oncology drug development, including registration trials and regulatory submissions and reviews, make him the optimal leader of our medical team," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer at Immune Design. "His esteemed career as an immunologist and oncologist spans industry, academia and clinical practice and will bring invaluable expertise and insight to guide the further advancement of our current Phase 2 stage products and our next-generation approaches in the field of cancer immunotherapy."     A board-certified, U.S. licensed hematologist/oncologist with more than 20 years of experience in immunology and oncology, Dr. Yurasov joins Immune Design from Clovis Oncology, where he most recently served as Senior Vice President, Clinical Development overseeing all clinical activities for its rociletinib, rucaparib and lucitanib programs, including regulatory approval and launch support for rociletinib and rucaparib.  Prior to Clovis, Dr. Yurasov served as Associate Vice-President, Global Medicine Science, at ImClone Systems, a subsidiary of Eli Lilly & Co. where he led the development of ramucirumab culminating in the FDA submission for second line non-small cell lung cancer indication. He also served at Hoffman-La Roche as Clinical Director of Oncology, Pharma Research and Early Development. Prior to his industry experience, Dr. Yurasov was Assistant Professor of Clinical Investigation at Rockefeller University, where he was the principal investigator for NIH funded translational immunology research, and Clinical Instructor in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center, where he was an attending physician. Dr. Yurasov received his M.D. from the Russian State Medical University and his Ph.D. in medical sciences from the Research Institute for Pediatric Oncology in Moscow, Russia.  He thereafter completed his residency in general pediatrics at Albert Einstein College of Medicine/Jacobi Medical Center and his subspecialty training in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center while serving as a research fellow at The Rockefeller University in Dr. M. Nussenzweig's laboratory.  



 








 










































If you liked this article you might like













5 Stocks Insiders Love Right Now
Insiders at these companies have been scooping up shares of their own stocks lately.



Roberto Pedone

Sep 28, 2016 3:06 PM EDT
























7 Stocks Spiking on Big Volume
Here's a technical look at how to trade seven stocks that are rising on unusual volume recently.



Roberto Pedone

Jun 21, 2016 7:49 AM EDT
























7 Stocks Making Big Moves on Unusual Volume
These stocks rising on unusual volume are within range of triggering breakout trades.



Roberto Pedone

Mar 29, 2016 9:18 AM EDT
























5 Stocks Insiders Love Right Now
Insiders at these companies have been scooping up shares o their own stock lately.



Roberto Pedone

Apr 29, 2015 7:00 AM EDT








































 


















Advertising Partners



 






 






 






 


























 

























 































 


©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.




Compare Brokers



 







 







 







 







 







 





















Immune Design Appoints Sergey Yurasov, M.D., Ph.D. As Senior Vice President Of Clinical Development And Chief Medical Officer - Pg.2 - TheStreet




































































 

 




















Action Alerts PLUS

Access AAPJim Cramer's Best Stocks for 2017Charitable Trust PortfolioMost Recent Trade Alert25 Investing Rules10 Trading Commandments

Real Money

Access RM25 Rules of InvestingJim Cramer's Best Stocks for 201710 CommandmentsStressed Out StocksCramer's Blog

Cramer
Mad Money
ETFs
Futures
Markets
Much More

BanksBiotechRetailTechPersonal FinanceRetirementFinancial Advisor CenterHow to SpendOptionsFixed IncomeVideo










Privacy Policy|Terms of Use© 1996- TheStreet Inc. All rights reserved
















                                DJIA
                            







                                NASDAQ
                            







                                S&P 500
                            






Market Data updated






Sign In




Your Membership(s)








Your Account





Account Preferences


Alerts


Newsletters







Subscribe





Logout



Subscribe

Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Income Seeker
Quant Ratings
Real Money
Real Money Pro
Stocks Under $10
Top Stocks
Trifecta Stocks
Real Money Pro Portfolio
Chairman's Club
Compare All 
Chatter on the Street













































 








































Immune Design Appoints Sergey Yurasov, M.D., Ph.D. As Senior Vice President Of Clinical Development And Chief Medical Officer






GlobeNewswire



Oct 4, 2016 8:00 AM EDT













 


















































 "Immune Design's immunotherapy approaches offer a promising approach to address the shortcomings of existing therapies, either alone or in combination with other agents," said Dr. Yurasov. "It is rewarding to be involved in such innovative science at the forefront of cancer research. I am pleased to join this distinguished team and look forward to help guide the development of these innovative product candidates."   About Immune Design Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases.  CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVex  ®  and GLAAS TM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.  Media ContactJulie RathbunRathbun Communicationsjulie@rathbuncomm.com 206-769-9219Investor ContactShari AnnesAnnes Associatessannes@annesassociates.com650-888-0902    



 








 










































If you liked this article you might like













5 Stocks Insiders Love Right Now
Insiders at these companies have been scooping up shares of their own stocks lately.



Roberto Pedone

Sep 28, 2016 3:06 PM EDT
























7 Stocks Spiking on Big Volume
Here's a technical look at how to trade seven stocks that are rising on unusual volume recently.



Roberto Pedone

Jun 21, 2016 7:49 AM EDT
























7 Stocks Making Big Moves on Unusual Volume
These stocks rising on unusual volume are within range of triggering breakout trades.



Roberto Pedone

Mar 29, 2016 9:18 AM EDT
























5 Stocks Insiders Love Right Now
Insiders at these companies have been scooping up shares o their own stock lately.



Roberto Pedone

Apr 29, 2015 7:00 AM EDT








































 


















Advertising Partners



 






 






 






 


























 

























 































 


©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.




Compare Brokers



 







 







 







 







 







 















Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft



















Yurasov Sergey - Immune Design Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsYurasov SergeyImmune Design (IMDZ)Sr. VP, Clinic. Devel. & CMO Not RankedYurasov Sergey's PerformanceYurasov Sergey has not reported any informative transactions and therefore cannot be ranked.How are Insiders Ranked? Yurasov Sergey's Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DateIMDZImmune DesignSr. VP, Clinic. Devel. & CMO-Uninformative Buy$0Jan 06, 2017Yurasov Sergey has not reported any informative transactions for IMDZ, therefore, performance cannot be measured. Track Record DateTransactionAmountNo. of SharesPrice per ShareProfitForm 4 Jan 06, 2017 Uninformative Buy $0 6,000 $5.25 N/A See All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by


























	Immune Design Corporation Appoints Sergey Yurasov M D Ph D As Senior Vice President Of Clinical Development And Chief Medical Officer













































Employer:
Login
Post Jobs


Job Seeker:
Login
Sign Up

























Search Life Sciences Jobs





Search Job Title Only












Radius:
Miles



Km80.5
















                 News | News By Subject | News by Disease |  
    News By Date | Search News



















Get Our FREEIndustry eNewsletter

email:


*
            
*
            



















 

 






Immune Design Corporation (IMDZ) Appoints Sergey Yurasov, M.D., Ph.D. As Senior Vice President Of Clinical Development And Chief Medical Officer  











Tweet








10/4/2016 7:48:12 AM




  Life Sciences Jobs
 


  &bullet; Newest Jobs - Last 24 Hours


  &bullet; California Jobs


  &bullet; Massachusetts Jobs


  &bullet; New Jersey Jobs


  &bullet; Maryland Jobs


  &bullet; Washington Jobs


  View More Jobs


 SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer. “Sergey’s extensive experience and successful track record in immunology and in the various stages of clinical oncology drug development, including registration trials and regulatory submissions and reviews, make him the optimal leader of our medical team,” said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer at Immune Design. “His esteemed career as an immunologist and oncologist spans industry, academia and clinical practice and will bring invaluable expertise and insight to guide the further advancement of our current Phase 2 stage products and our next-generation approaches in the field of cancer immunotherapy.”     A board-certified, U.S. licensed hematologist/oncologist with more than 20 years of experience in immunology and oncology, Dr. Yurasov joins Immune Design from Clovis Oncology, where he most recently served as Senior Vice President, Clinical Development overseeing all clinical activities for its rociletinib, rucaparib and lucitanib programs, including regulatory approval and launch support for rociletinib and rucaparib.  Prior to Clovis, Dr. Yurasov served as Associate Vice-President, Global Medicine Science, at ImClone Systems, a subsidiary of Eli Lilly & Co. where he led the development of ramucirumab culminating in the FDA submission for second line non-small cell lung cancer indication. He also served at Hoffman-La Roche as Clinical Director of Oncology, Pharma Research and Early Development. Prior to his industry experience, Dr. Yurasov was Assistant Professor of Clinical Investigation at Rockefeller University, where he was the principal investigator for NIH funded translational immunology research, and Clinical Instructor in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center, where he was an attending physician. Dr. Yurasov received his M.D. from the Russian State Medical University and his Ph.D. in medical sciences from the Research Institute for Pediatric Oncology in Moscow, Russia.  He thereafter completed his residency in general pediatrics at Albert Einstein College of Medicine/Jacobi Medical Center and his subspecialty training in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center while serving as a research fellow at The Rockefeller University in Dr. M. Nussenzweig’s laboratory. "Immune Design’s immunotherapy approaches offer a promising approach to address the shortcomings of existing therapies, either alone or in combination with other agents," said Dr. Yurasov. "It is rewarding to be involved in such innovative science at the forefront of cancer research. I am pleased to join this distinguished team and look forward to help guide the development of these innovative product candidates."  About Immune Design  Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases.  CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVex® and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.  Media Contact Julie Rathbun Rathbun Communications julie@rathbuncomm.com 206-769-9219 Investor Contact Shari Annes Annes Associates sannes@annesassociates.com 650-888-0902     






                Read at
                BioSpace.com







Related News
Immune Design Corporation (IMDZ) Announces Advancement Of First GLAAS-Based Allergy Program Into Clinical Development  How Trump Was Named "Grand Benefactor" For A Dana-Farber Cancer Institute Gala Without Donating A Penny  Immune Design Corporation (IMDZ) Prices Public Offering Of Common Stock  How Mylan (MYL) CEO's Mom Helped Boost EpiPen Sales  Immune Design Corporation (IMDZ) Announces Proposed Public Offering Of Common Stock  Boston Therapeutics Completes Private Offering, Appoints New CEO   Immune Design Corporation (IMDZ) Reports Second Quarter 2016 Financial Results And Provides Corporate Update  The Scientific Advisors at  Theranos Won't (or Can't) Talk  ASCO2016: Immune Design Corporation (IMDZ) Releases New PFS, OS And TME Data From Trials Of Three Immuno-Oncology Product Candidates  Mylan (MYL) CEO Draws Fire Over Use of Private Jet  




Please enable JavaScript to view the comments powered by Disqus.
comments powered by Disqus






















                            •
                            BioSpace.com










                            •
                            Immune Design Corporation




             
        





                            •
                            Biotech/Pharma - Personnel




             
        















                              
                            

                              
                             
                              
                            

                              
                            








                 





























Immune Design Appoints Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer - PharmaVOICE  : PharmaVOICE                                        READ. THINK. PARTICIPATE.    SUBSCRIBE | REGISTER | LOG IN XSite Login Username  Password  Lost your password?  Don't have an account?Click here to register for free.Benefits of Registered UsersRegistered user can access and download all content.Have a Question?Email Customer ServiceCall (215)321-8656Proceed as Guest  Download as Guest Guests must provide the below information each time you download content from PharmaVOICE.com.Content will be sent to your inbox. Email *   First Name *    Last Name *   Title *  Company *    Don't have an account?Click here to register.Benefits of Registered Users Registered user can access and
download all content without
inputting information multiple
times for multiple downloadsGet your free subscription to PharmaVOICE MagazineClick one of the links below to pick what type of subscription you'd like.  It's completely free. PharmaVOICE Print and Digital Subscription PharmaVOICE Digital Subscription Only PharmaVOICE Print Subscription OnlyAlready subscribed?Click here to loginHave a Question?Email Customer ServiceCall (215)321-8656Forgot your password?Fill out the form below and we will email you a new one.  All you have to do is check your mail and you will be directed back to PharmaVOICE.com Email or Username  Remember your password?Click here to login.Have a Question?Contact Customer ServiceNewsBlogR&DCommercialOperationsCurrent IssueMagazineCurrent IssueDigital EditionArchivesEditorialAdvertiseCirculationReprintsList RentalsSubscribePharmaVOICE 100PharmaVOICE 100 CelebrationNominateSubmission GuidelinesCurrent 100Red Jacket AwardContact EditorResourcesArticlesCase StudieseBooksPodcastsWebinarsWhite PapersVideosEventsPharmaVOICE 100 CelebrationIndustry EventsWebinarsEditorialEditorial CalendarEditorial ScopePhotography GuidelinesPharmaVOICE 100Innovation IssueContact EditorAdvertisePrint AdvertisingOnline AdvertisingE-mail AdvertisingMarketing SolutionsTerms and ConditionsContact PublisherSubscribeMagazine SubscriptionPharmaVOICE 100 CelebrationHomeView Digital EditionMagazineNewsBlogCase StudieseBooksPodcastsWebinarsWhite PapersVideosAdvertiseSubscribe      All News Releases Upload News ReleaseNews Release Immune Design Appoints Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer Source:GLOBE NEWSWIRE October 4, 2016SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) — Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer.“Sergey’s extensive experience and successful track record in immunology and in the various stages of clinical oncology drug development, including registration trials and regulatory submissions and reviews, make him the optimal leader of our medical team,” said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer at Immune Design. “His esteemed career as an immunologist and oncologist spans industry, academia and clinical practice and will bring invaluable expertise and insight to guide the further advancement of our current Phase 2 stage products and our next-generation approaches in the field of cancer immunotherapy.”A board-certified, U.S. licensed hematologist/oncologist with more than 20 years of experience in immunology and oncology, Dr. Yurasov joins Immune Design from Clovis Oncology, where he most recently served as Senior Vice President, Clinical Development overseeing all clinical activities for its rociletinib, rucaparib and lucitanib programs, including regulatory approval and launch support for rociletinib and rucaparib. Prior to Clovis, Dr. Yurasov served as Associate Vice-President, Global Medicine Science, at ImClone Systems, a subsidiary of Eli Lilly & Co. where he led the development of ramucirumab culminating in the FDA submission for second line non-small cell lung cancer indication. He also served at Hoffman-La Roche as Clinical Director of Oncology, Pharma Research and Early Development. Prior to his industry experience, Dr. Yurasov was Assistant Professor of Clinical Investigation at Rockefeller University, where he was the principal investigator for NIH funded translational immunology research, and Clinical Instructor in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center, where he was an attending physician.Dr. Yurasov received his M.D. from the Russian State Medical University and his Ph.D. in medical sciences from the Research Institute for Pediatric Oncology in Moscow, Russia. He thereafter completed his residency in general pediatrics at Albert Einstein College of Medicine/Jacobi Medical Center and his subspecialty training in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center while serving as a research fellow at The Rockefeller University in Dr. M. Nussenzweig’s laboratory.“Immune Design’s immunotherapy approaches offer a promising approach to address the shortcomings of existing therapies, either alone or in combination with other agents,” said Dr. Yurasov. “It is rewarding to be involved in such innovative science at the forefront of cancer research. I am pleased to join this distinguished team and look forward to help guide the development of these innovative product candidates.”About Immune DesignImmune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design’s ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVex® and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com. Feature This Posted in: Human Resources, OperationsPost a Comment Click here to cancel reply.You must be logged in to post a Comment. FeaturedNews Releases  Agile Therapeutics Reports Second Quarter 2017 Financial Results Source:GLOBE NEWSWIRE July 28, 2017 View  Agios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017 Source:GLOBE NEWSWIRE July 28, 2017 View  Penicillin Market 2017 Company Profile, Industry Trends, Share, Size and 2022 Forecasts Says a new Research Report at ReportsnReports Source:PRNewswire July 28, 2017 View  Cesca Therapeutics Announces Issuance of New Cellular Processing Patent Poised to Revolutionize CAR-T Cell Manufacturing Source:GLOBE NEWSWIRE July 28, 2017 View  U.S. Court of Appeals for the Federal Circuit Affirms Merus’ Inequitable Conduct Claim Against Regeneron Source:GLOBE NEWSWIRE July 28, 2017 View   Current Issue  June 2017  Digital Edition  Extra Copies  Reprints  Subscriptions  SUBSCRIBE FOR FREE ACCESSGet free access to PharmaVOICE magazine,
webinars, white papers, podcasts, videos,
article downloads, tips, and event
discounts delivered to your inbox!           CoverageCurrent IssueNewsBlogResourcesCase StudieseBooksPodcastsWebinarsWhite PapersVideosUser CenterSubscribeAdvertiseAbout UsContact UsSubscribeConnect With UsNewslettersTwitterLinked InFacebookGoogle+HomeAdvertiseBlogContact©  2017 PharmaVOICE All rights reserved. FEEDBACK                                         


	Sergey Yurasov | Profile | Scrum Alliance




































































Get certified - Transform your world of work today


Menu
Sign In



















Menu












Community





Certificant Directory


Expert Perspectives: Spotlight


Member Articles 


News


Sponsorship Application







About Us




FAQs









Home » Community








                    Sergey Yurasov
                  
                Delivery Director, First Line Software
Location: Nizhny Novgorod













Certifications
Certified ScrumMaster





Credentials





Links
http://firstlinesoftware.com/






Biography
LinkedIn Profile

First Line Software







Find a course »

Certified ScrumMaster
Certified Scrum Product Owner
Certified Scrum Developer
Certified Agile Leadership

Continuing Education »
Virtual Learning »


Find Education Providers »

Certified Scrum Trainer
Certified Enterprise Coach
Registered Education Provider




















			 






Newsletter Sign-Up
Subscribe






















































